NCT05294731RECRUITINGanonymous

A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies

Sponsor

Source record

BeiGene

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

BGB-16673

Indication / condition

AI-normalized

B-cell Malignancy

Intervention

Source record

BGB-16673

Related intelligence directories

Indication directory: B-cell Malignancy Modality directory: small molecule Target directory: BGB-16673

Source & freshness

Source record

NCT ID

NCT05294731

Original source

ClinicalTrials.gov

Source last updated

Apr 17, 2026

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05294731

Title

A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies

Sponsor

BeiGene

Status

RECRUITING

Phase

PHASE1

Condition raw

B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia, Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Unclassifiable, Richter's Transformation

Condition normalized

Modality raw

small molecule

Modality normalized

small molecule

Target raw

BGB-16673

Target normalized

BGB-16673

Interventions

BGB-16673

Public preview

Source record

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT05294731

Status

RECRUITING

Phase

PHASE1

Sponsor

BeiGene

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 17, 2026

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05294731

Indication

B-cell Malignancy

Modality

small molecule

Target

BGB-16673

Intervention

BGB-16673

Source record